

Special Issue

Viral Vectors Paired with Genome-Editing Tools: Evolving Technologies for the Treatment of Neurodegenerative Diseases and Disorders

Message from the Guest Editors

Diseases and disorders of the central nervous system (CNS) have historically been among the most difficult to combat using conventional pharmacological strategies. In this chapter, we describe the various tools available for genome editing and summarize in vitro and in vivo preclinical studies of CNS genome editing. We discuss the future progress of these technologies, as well as the current limitations and alternative approaches to overcoming some of their bottlenecks. We will aim here to devote significant attention to viral vectors derived from human immunodeficiency virus type 1 (lentiviral vectors; LVs) and adeno-associated virus (AAVs). The high interest in these viral delivery systems vectors is due to: (i) robust delivery and long-lasting expression; (ii) efficient transduction into postmitotic cells, including the brain; (iii) low immunogenicity and toxicity; and (iv) compatibility with advanced manufacturing techniques. Finally, this chapter will summarize the current therapeutic application and novel approaches of advance genome-editing technology for the prevention and treatment of neurodegenerative diseases (NDDs).

Guest Editors

Dr. Boris Kantor

Director of Viral Vector Core, Department of Neurobiology, Duke University School of Medicine, Durham, NC 27710, USA

Prof. Dr. Ornit Chiba-Falek

Division of Translational Brain Sciences, Department of Neurology & Pathology, and the Center for Genomic and Computational Biology, Duke University Medical Center, Durham, NC 27710, USA

Deadline for manuscript submissions

closed (31 May 2022)



Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



mdpi.com/si/106316

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

[mdpi.com/journal/](https://mdpi.com/journal/cells)

[cells](https://mdpi.com/journal/cells)





Cells

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed



[mdpi.com/journal/
cells](https://mdpi.com/journal/cells)



About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny

Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE,
Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch

Biotech Research & Innovation Centre, The University of Copenhagen,
Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).